Skip Navigation
Menu Search
Pediatric Oncology

In This Section      

The Pratilas Laboratory

Pratilas Lab Staff

Our lab focuses on the application of small molecule therapeutics to solid tumors harboring oncogenic activation of RAS and RAS effector pathways. We emphasize interrogation of biochemical and adaptive signaling responses to small molecule inhibition of the ERK signaling pathway, to identify factors that predict and condition response to targeted therapeutics.

Our current projects:

Latest News:

Abstracts:

  • AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, October 2019.
  • A121, Sunday October 27 – Wang et al. Adaptive and acquired signaling response to MEK inhibition in NF1-associated malignant peripheral nerve sheath tumor.
  • B066, Monday October 28 – Obasaju et al. Inhibition of farnesyl transferase by tipifarnib leads to isoform specific cell growth inhibition in HRAS-mutated human rhabdomyosarcoma.
  • B074, Monday October 28 – Schreck et al. Sapanisertib in combination with trametinib in glioblastoma models enhances target inhibition and antitumor activity.

Our Lab's Discoveries:

Other Recent Publications from Christine Pratilas: